Dipòsit Digital de la Universitat de Barcelona
metadata only
CC BY 4.0
A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: a structured summary of a study protocol for a randomised controlled trial
Objectives: Baricitinib is supposed to have a double effect on SARS-CoV2 infection. Firstly, it reduces the inflammatory response through the inhibition of the Januse-Kinase signalling transducer and activator of transcription (JAK-STAT) pathway. Moreover, it reduces the receptor mediated viral endo
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Tofacitinib in Hospitalized Patients With COVID-19 Pneumonia#912618
- TOFAcitinib in SARS-CoV2 Pneumonia#1163298
- Utility of Lactoferrin as an Adjunct Therapeutic Agent for COVID-19#871590
- Efficacy and Safety of Baricitinib in the Post-intracerebral Hemorrhage Pulmonary Injury#864011
- Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants#967790
Record · ID 1324007
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive